Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, presents the results of the phase 3 CheckMate 238 trial (NCT02388906), which looked at adjuvant nivolumab vs. ipilimumab in resected stage III/IV melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.